Featured Research

from universities, journals, and other organizations

Experimental Drug Used To Treat Recurrent Ovarian Cancer Shows Promising Results

Date:
February 23, 2004
Source:
Yale University
Summary:
Yale researchers have reported promising preliminary results of a Phase Ib/IIa study in women with recurrent ovarian cancer using phenoxodiol, an experimental anti-cancer drug that could kill cancer cells and increase effectiveness of standard chemotherapy.

Yale researchers have reported promising preliminary results of a Phase Ib/IIa study in women with recurrent ovarian cancer using phenoxodiol, an experimental anti-cancer drug that could kill cancer cells and increase effectiveness of standard chemotherapy.

Related Articles


The data were presented by David O'Malley, M.D., instructor, Department of Obstetrics, Gynecology & Reproductive Sciences, at the 35th Annual Meeting of the Society of Gynecologic Oncologists in San Diego, California on February 8. The researchers found no toxicity, 25 percent response and synergy with chemotherapy. The main purpose of the study was to determine the dose of phenoxodiol to be used in combination with other anti-cancer drugs.

While phenoxodiol has the ability to stop ovarian cancer growth in animals in its own right, Yale researchers and the drug's developer, Marshall Edwards, Inc., are developing the drug in late-stage ovarian cancer as a chemo-sensitizer, restoring the sensitivity of the cancer cells to standard chemotherapeutic drugs.

"Patients received phenoxodiol twice a week, which is how we believe it will be used in combinational therapy," said principal investigator Thomas Rutherford, M.D., associate professor of gynecology, Department of Obstetrics, Gynecology & Reproductive Sciences. "We did expect to see a major anti-tumor effect when used at this dose, with an apparent 25 percent stability rate in unresponsive cancers. These results gave us confidence in the potential use of phenoxodiol for the treatment of ovarian cancer. We are highly encouraged by the outcome."

The data reflected outcomes from the first 20 of 40 patients enrolled in the study with late-stage ovarian cancer that had become unresponsive to standard chemotherapy. Of the 20 patients who started the course of treatment, 13 were able to finish a three-month program without disease progression. Five of these patients were evaluated to have disease stabilization; all these patients later progressed.

In a follow up of the study, eight of nine patients who were treated with paclitaxel-standard chemotherapy-following completion of the phenoxodiol trial showed a positive serologic response to paclitaxel therapy. Four of these patients had previously been defined as paclitaxel resistant.

"This is a preliminary observation only, but one that we find highly encouraging because it confirms in humans what we saw in the laboratory -- that phenoxodiol is a powerful chemo-sensitizer," said Gil Mor, M.D., PhD, associate professor and a co-investigator in the study.


Story Source:

The above story is based on materials provided by Yale University. Note: Materials may be edited for content and length.


Cite This Page:

Yale University. "Experimental Drug Used To Treat Recurrent Ovarian Cancer Shows Promising Results." ScienceDaily. ScienceDaily, 23 February 2004. <www.sciencedaily.com/releases/2004/02/040223074256.htm>.
Yale University. (2004, February 23). Experimental Drug Used To Treat Recurrent Ovarian Cancer Shows Promising Results. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2004/02/040223074256.htm
Yale University. "Experimental Drug Used To Treat Recurrent Ovarian Cancer Shows Promising Results." ScienceDaily. www.sciencedaily.com/releases/2004/02/040223074256.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Nurse Nina Pham Cured of Ebola

Texas Nurse Nina Pham Cured of Ebola

AFP (Oct. 25, 2014) — An American nurse who contracted Ebola while caring for a Liberian patient in Texas has been declared free of the virus and will leave the hospital. Duration: 01:01 Video provided by AFP
Powered by NewsLook.com
IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) — The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins